No fearmongering /just facts on yesterday someone posting on eye issues Finasteride/Dutasteride 5/5/2025
Finasteride and dutasteride may not significantly impact meibomian gland function since these glands do not rely on DHT. Some users report dry eyes and other side effects from finasteride, but these may be influenced by other factors or medications.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity NEW STUDY :why finasteride and dutasteride does not cause dry eyes
Finasteride and Dutasteride do not cause dry eyes by damaging meibomian glands, as these glands continue to function normally even when DHT is blocked. Some users report dry eyes with these medications, but others suggest supplements like Omega-3 or krill oil as potential remedies.
community Finasteride and Eye Problems: You’re Not Going Crazy
Finasteride can cause dry eyes and vision issues due to its impact on the meibomian glands. Users have mixed experiences, with some experiencing eye discomfort and others having no side effects.
community Blaming Finasteride doesn't help you solve anything: dry eyes
Finasteride is debated for causing dry eyes, with some users experiencing relief after stopping it, while others find no connection. Topical treatments like dutasteride and minoxidil are suggested as alternatives, with advice to consult medical professionals.
community Does finasteride/dutasteride reverse aging?
Finasteride and dutasteride can improve skin texture and reduce acne by lowering DHT but do not reverse aging. They may enhance skin and hair health for some, but can also cause side effects like dry skin and sexual dysfunction.
community Severe dry eye: finasteride vs dutasteride
Woman uses antiandrogens for hair thinning prevention, experiences severe dry eye with finasteride. Asks if dutasteride could be better despite potential for worse dry eye.
Related Research
6 / 6 resultsresearch Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’s Time to Sound the Alarm
This article discusses the potential health risks associated with long-term use of finasteride and dutasteride for prostate and hair loss treatments, suggesting risks may include non-alcoholic fatty liver disease, insulin resistance, type 2 diabetes, and other metabolic issues.
research Genetic Insights into Acne, Androgenetic Alopecia, and Alopecia Areata: Implications for Mechanisms and Precision Dermatology
This study examines the genetic underpinnings of chronic dermatological conditions like acne, androgenetic alopecia, and alopecia areata, concluding that a deep understanding of these mechanisms can advance patient-specific treatments and inform cosmetic practices related to skin and hair health.
research Drugs linked to blepharitis, meibomian gland dysfunction, and chalazion: a real-world, population-based pharmacovigilance analysis
This pharmacovigilance study found that certain systemic medications, including finasteride, bortezomib, and dupilumab, were disproportionately reported in association with eyelid disorders like blepharitis, meibomian gland dysfunction, and chalazia, suggesting these drugs may contribute to these conditions though benefits might still outweigh the risks.
research Characterization of X‐linked hypohidrotic ectodermal dysplasia (XL‐HED) hair and sweat gland phenotypes using phototrichogram analysis and live confocal imaging
People with X-linked hypohidrotic ectodermal dysplasia have no sweat ducts and less, thinner hair.
research The Association Between 5α-Reductase Inhibitors and the Presence of Subsequent Dry Eye Disease in Androgenetic Alopecia: A TriNetX Database Study
In this retrospective cohort study, researchers found that patients with androgenetic alopecia using 5α-reductase inhibitors had a significantly higher risk of developing dry eye disease compared to those not using these medications.
research Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology
This consensus concluded that oral isotretinoin is highly effective for treating acne and some off-label conditions, with common adverse events being manageable and rare serious risks not contraindicating use.